2025 Q4 -tulosraportti
8 päivää sitten
‧36 min
1,00 NOK/osake
Viimeisin osinko
30,54%Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 300 | - | - | ||
| 2 166 | - | - | ||
| 2 575 | - | - | ||
| 1 574 | - | - | ||
| 87 | - | - |
Ylin
3,59VWAP
Alin
3,18VaihtoMäärä
5,3 1 559 379
VWAP
Ylin
3,59Alin
3,18VaihtoMäärä
5,3 1 559 379
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenIf phase-2 or early phase-3 data are strong, a large pharmaceutical company often buys the technology. Any thoughts on that here? It's annoying to invest in a journey one can believe in, only for it to abruptly stop with a typical acquisition. Regards from someone who eventually hopes to be part of the whole journey.
·1 t sittenPersonally, I operate with a three-digit number at acquisition. Then what happens, happens. Today's trading indicates that some do not believe the same as me.
·4 t sitten🧪 Breakthrough in Boston: ASIT Summit (March 3, 2026) Nykode has now delivered what is called "Preclinical Proof of Concept" (PoC) for its tolerance platform. While the cancer vaccine teaches the body to attack, this technology teaches the immune system to calm down (tolerate). • Breakthrough in Vitiligo: New data shows a significant reduction in CD8+ T-cells in the skin. In Vitiligo, it is precisely these cells that mistakenly attack the pigment cells. This proves for the first time that the platform works on autoimmune skin conditions. [Source: Nykode Press Release, 03.03.2026] • Regulatory T-cells (Tregs): The presentation documented that Nykode's targeting of APC receptors creates Tregs. These are the body's "peacekeepers" that switch off inflammation without otherwise weakening the immune system. This is the "holy grail" in autoimmunity. [Source: Nykode Press Release, 03.03.2026] • Effect after disease onset: In models for Multiple Sclerosis (EAE), the treatment reduced auto-antibodies even when administered after symptoms had appeared – a critical proof for clinical use in humans. [Source: Nykode Q4 report p. 21, 25.02.2026] 💰 Market Potential and Valuation Many underestimate the value of early-stage data, but in the field of immune tolerance, large pharmaceutical companies (Big Pharma) often pay billions to secure the technology before it reaches human studies. • Vitiligo Market: Globally, the market for Vitiligo treatment is estimated at approximately 1.7 billion dollars in 2026, with an expected growth to over 2.2 billion dollars by 2031. Biological therapies are growing fastest at over 15% annually. [Source: Mordor Intelligence / Business Research Company, Feb 2026] • Comparable deals: * Sonoma Biotherapeutics: Received 75 million dollars upfront (approx. 800 million NOK) from Regeneron for a similar Treg platform. [Source: Regeneron/Sonoma PR, 11.01.2023] • Anokion: Eli Lilly has invested over 100 million dollars in a platform with the same mechanism as Nykode's ASIT. [Source: Eli Lilly Partnership Update, 2024] 📈 Updated Scenarios (Bear, Base, Bull) At today's share price of 3.53 kr, the technology is valued at only approx. 70 øre above the company's pure liquidation value (cash + tax claim). 1. BEAR CASE: "Oncology disappointment" If the detailed data in Seville (March 20) shows that the cancer response is not durable. • Price target: 2.50 – 2.80 kr. • Assessment: The floor in the stock has now been significantly raised because the ASIT platform functions as a validated «Asset B». The downside is practically covered by cash (1.84 kr) and the tax claim (1.00 kr). [Source: Cash calculation based on Q4 report p. 5, 25.02.2026] 2. BASE CASE: "Normalization" If the cancer data on March 20 confirms 38.5% response with stable duration. • Price target: 6.50 – 8.50 kr. • Assessment: The market is starting to price Nykode as a platform company with two legs. The risk is no longer binary, and the valuation will approach historical multiples for phase 2 companies. 3. BULL CASE: "The Big Exit" If the Seville data shows deep, durable responses (TCR proof) while ASIT interest increases. • Price target: 16.00 – 22.00 kr. • Assessment: This scenario prices in a value equivalent to Merck's acquisition of EyeBio ($1.3 billion upfront). With such a valuation, both a global cancer vaccine and a leading tolerance platform are reflected. [Source: Merck/EyeBio Comparison, May 2024] ℹ️ Important information for investors For supplementary information and the actual scientific slides from the Boston presentation, follow "Scientific Publications" on Nykode's investor pages in the coming days. Disclaimer: I own shares in Nykode Therapeutics myself. This analysis is based on publicly available information and represents my own assessments. Investments in biotechnology involve very high risk, and there is no guarantee of positive returns or profit. You should always conduct your own thorough analysis before investing. 📚 Sources and URL References • Nykode Q4 2025 Financial Report (25.02.2026): Figures for cash balance (60.3 million USD) and guidance for the tax case (1H 2026). • URL: https://nykode.com/investors/financial-reports/ • Nykode Press Release - ASIT Summit Boston (03.03.2026): Details on Vitiligo data, Tregs and CD8+ reduction. • URL: https://nykode.com/media/news-and-announcements/ • Vitiligo Treatment Market Forecast (February 2026): Market size of 1.69 billion USD. • URL: https://www.mordorintelligence.com/industry-reports/vitiligo-treatment-market • Regeneron & Sonoma Biotherapeutics Partnership (11.01.2023): Upfront value of 75 million USD for Treg platform. • URL: https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sonoma-biotherapeutics-announce-collaboration/ • Eli Lilly & Anokion Partnership Update (2024/2025): Investment levels in antigen-specific tolerance. • URL: https://investor.lilly.com/news-releases/ Do you have more to add? It's good to present all data for a thorough analysis. 🧐- ·23 t sitten🎯 Nykode: The run-up to Sevilla (March 20) – Bear, Base & Bull After weeks of "free fall," we now see signs of bottom formation around NOK 2.90–3.20. While the market has been characterized by fear, the clinical facts remain firm. Here's what we're looking for in Sevilla and what it means for the share price: 🛡️ The Foundation (Cash Floor): NOK 2.78 Before we look up, we must look down. Nykode currently has cash reserves of approx. NOK 1.78/share + a probable tax claim of NOK 1.00/share (answer expected 1H 2026). • Conclusion: At today's prices, the technology is valued at almost zero. 🐻 BEAR Case: "The Keytruda Flash" • Data: Short-lived responses (under 6 months), weak link between T-cells and tumor shrinkage. • Narrative: The market believes the results are due to luck or Keytruda alone. • Price Target: NOK 2.00 – 2.50 (Technology valued at zero, stock trades below cash value). ⚖️ BASE Case: "Solid, but Waiting" • Data: Confirmed 38.5 % ORR with stable duration. T-cell data shows the vaccine is working, but no "extreme" outcomes. • Narrative: De-risking of the platform, but the market will wait for Abili-T (2027) before full repricing. • Price Target: NOK 4.50 – 6.00 (Normalization to the levels before February's panic fall). 🚀 BULL Case: "The EyeBio-Moment" • Data: "Spider Plots" showing Durable Response (9+ months), TCR evidence for vaccine cells inside the tumor, and perhaps a conversion from PR to CR (tumor completely gone). • Narrative: Nykode doubles the effect of standard treatment. The comparison with Merck's acquisition of EyeBio ($1.3 billion upfront for early-stage data) becomes impossible to ignore. • Price Target: NOK 12.00 – 18.00 (The market begins to price in a real acquisition probability). 🔍 What should we look for on the slides? 1. Spider Plots: Look for flat lines below the -30 % threshold. Duration is everything! 2. TCR-graphs: Evidence that the vaccine T-cells actually find their way into the tumor. 3. Ongoing Responses: Small arrows at the end of the graphs, meaning the patient is still alive and responding. Summary: On March 20 at 15:15 in Sevilla, we will get the answer whether the technology is worth 13 øre or 60 kroner. With a downside that is practically covered by cash, the risk/reward ratio is unique. Thoughts? Anything else we should look for or that hasn't been considered?
- ·1 päivä sittenAnyone starting to realize that the stock is dirt cheap? About time.
·1 päivä sitten · MuokattuCan there be a bid for the company!? Of course, but what is the probability? 📍Time aspect; well, by the end of the year 📍Price; 10ish probably makes the major shareholders move 📍More players entering the field? Well 📍The company is tired of Norway and the stock exchange here, I think they would gladly see a listing and fresh start elsewhere. 📍Am I speculating? YES 📍Am I long? YES
1 päivä sitten1 päivä sittenI don't think it's unthinkable that the therapy has a value of 2B dollars. Divide that by 326 million outstanding shares that's around 6 dollars per share? Or am I being too optimistic? Then there's other therapies in the pipeline on top....·1 päivä sittenVery good timing on that calculation, Mr. Parker. As we see in today's price development towards 3.3 kr, the bottom at 2.892kr has proven to be the 'floor' that fundamental values require. To elaborate on your valuation discussion with the latest figures from the Q4 report: 1. Liquidation Value (Cash Floor): With a cash balance of approx. 582 mill. kr (60.3 mill. USD) and the impending tax refund of 325 mill. kr, Nykode has a 'liquidation value' of approx. 2.78 kr per share. • At price 2.91 kr: The market valued the technology at only 13 øre per share. • At price 3.30 kr: The market now values the technology at 52 øre per share. 2. Decision in the tax case in 1H 2026: The company confirmed last week that they expect a decision during the first half of the year. This removes much of the dilution threat (emission fear) that has kept the price down. If an analysis of an asset value of 2 mrd. dollar materializes, today's pricing of the technology (52 øre) is still an extreme undervaluation compared to the 60 kr per share such a value would imply. 3. Strategic Option (Merck/MSD): When we look at Merck's acquisition of EyeBio (AMD) for 1.3 mrd. USD upfront with data from only approx. 30 patients, the parallel to Nykode's current position is striking. We are only weeks away from complete data documentation on ICHNO March 20. That the price is now reacting up from the 2.89-level indicates that investors are starting to see the same as us: That the risk/reward ratio is completely unique when one can buy a platform with a confirmed 38.5 % response rate at a price that barely exceeds the value of the cash in the till.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
8 päivää sitten
‧36 min
1,00 NOK/osake
Viimeisin osinko
30,54%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenIf phase-2 or early phase-3 data are strong, a large pharmaceutical company often buys the technology. Any thoughts on that here? It's annoying to invest in a journey one can believe in, only for it to abruptly stop with a typical acquisition. Regards from someone who eventually hopes to be part of the whole journey.·1 t sittenPersonally, I operate with a three-digit number at acquisition. Then what happens, happens. Today's trading indicates that some do not believe the same as me.
- ·4 t sitten🧪 Breakthrough in Boston: ASIT Summit (March 3, 2026) Nykode has now delivered what is called "Preclinical Proof of Concept" (PoC) for its tolerance platform. While the cancer vaccine teaches the body to attack, this technology teaches the immune system to calm down (tolerate). • Breakthrough in Vitiligo: New data shows a significant reduction in CD8+ T-cells in the skin. In Vitiligo, it is precisely these cells that mistakenly attack the pigment cells. This proves for the first time that the platform works on autoimmune skin conditions. [Source: Nykode Press Release, 03.03.2026] • Regulatory T-cells (Tregs): The presentation documented that Nykode's targeting of APC receptors creates Tregs. These are the body's "peacekeepers" that switch off inflammation without otherwise weakening the immune system. This is the "holy grail" in autoimmunity. [Source: Nykode Press Release, 03.03.2026] • Effect after disease onset: In models for Multiple Sclerosis (EAE), the treatment reduced auto-antibodies even when administered after symptoms had appeared – a critical proof for clinical use in humans. [Source: Nykode Q4 report p. 21, 25.02.2026] 💰 Market Potential and Valuation Many underestimate the value of early-stage data, but in the field of immune tolerance, large pharmaceutical companies (Big Pharma) often pay billions to secure the technology before it reaches human studies. • Vitiligo Market: Globally, the market for Vitiligo treatment is estimated at approximately 1.7 billion dollars in 2026, with an expected growth to over 2.2 billion dollars by 2031. Biological therapies are growing fastest at over 15% annually. [Source: Mordor Intelligence / Business Research Company, Feb 2026] • Comparable deals: * Sonoma Biotherapeutics: Received 75 million dollars upfront (approx. 800 million NOK) from Regeneron for a similar Treg platform. [Source: Regeneron/Sonoma PR, 11.01.2023] • Anokion: Eli Lilly has invested over 100 million dollars in a platform with the same mechanism as Nykode's ASIT. [Source: Eli Lilly Partnership Update, 2024] 📈 Updated Scenarios (Bear, Base, Bull) At today's share price of 3.53 kr, the technology is valued at only approx. 70 øre above the company's pure liquidation value (cash + tax claim). 1. BEAR CASE: "Oncology disappointment" If the detailed data in Seville (March 20) shows that the cancer response is not durable. • Price target: 2.50 – 2.80 kr. • Assessment: The floor in the stock has now been significantly raised because the ASIT platform functions as a validated «Asset B». The downside is practically covered by cash (1.84 kr) and the tax claim (1.00 kr). [Source: Cash calculation based on Q4 report p. 5, 25.02.2026] 2. BASE CASE: "Normalization" If the cancer data on March 20 confirms 38.5% response with stable duration. • Price target: 6.50 – 8.50 kr. • Assessment: The market is starting to price Nykode as a platform company with two legs. The risk is no longer binary, and the valuation will approach historical multiples for phase 2 companies. 3. BULL CASE: "The Big Exit" If the Seville data shows deep, durable responses (TCR proof) while ASIT interest increases. • Price target: 16.00 – 22.00 kr. • Assessment: This scenario prices in a value equivalent to Merck's acquisition of EyeBio ($1.3 billion upfront). With such a valuation, both a global cancer vaccine and a leading tolerance platform are reflected. [Source: Merck/EyeBio Comparison, May 2024] ℹ️ Important information for investors For supplementary information and the actual scientific slides from the Boston presentation, follow "Scientific Publications" on Nykode's investor pages in the coming days. Disclaimer: I own shares in Nykode Therapeutics myself. This analysis is based on publicly available information and represents my own assessments. Investments in biotechnology involve very high risk, and there is no guarantee of positive returns or profit. You should always conduct your own thorough analysis before investing. 📚 Sources and URL References • Nykode Q4 2025 Financial Report (25.02.2026): Figures for cash balance (60.3 million USD) and guidance for the tax case (1H 2026). • URL: https://nykode.com/investors/financial-reports/ • Nykode Press Release - ASIT Summit Boston (03.03.2026): Details on Vitiligo data, Tregs and CD8+ reduction. • URL: https://nykode.com/media/news-and-announcements/ • Vitiligo Treatment Market Forecast (February 2026): Market size of 1.69 billion USD. • URL: https://www.mordorintelligence.com/industry-reports/vitiligo-treatment-market • Regeneron & Sonoma Biotherapeutics Partnership (11.01.2023): Upfront value of 75 million USD for Treg platform. • URL: https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sonoma-biotherapeutics-announce-collaboration/ • Eli Lilly & Anokion Partnership Update (2024/2025): Investment levels in antigen-specific tolerance. • URL: https://investor.lilly.com/news-releases/ Do you have more to add? It's good to present all data for a thorough analysis. 🧐
- ·23 t sitten🎯 Nykode: The run-up to Sevilla (March 20) – Bear, Base & Bull After weeks of "free fall," we now see signs of bottom formation around NOK 2.90–3.20. While the market has been characterized by fear, the clinical facts remain firm. Here's what we're looking for in Sevilla and what it means for the share price: 🛡️ The Foundation (Cash Floor): NOK 2.78 Before we look up, we must look down. Nykode currently has cash reserves of approx. NOK 1.78/share + a probable tax claim of NOK 1.00/share (answer expected 1H 2026). • Conclusion: At today's prices, the technology is valued at almost zero. 🐻 BEAR Case: "The Keytruda Flash" • Data: Short-lived responses (under 6 months), weak link between T-cells and tumor shrinkage. • Narrative: The market believes the results are due to luck or Keytruda alone. • Price Target: NOK 2.00 – 2.50 (Technology valued at zero, stock trades below cash value). ⚖️ BASE Case: "Solid, but Waiting" • Data: Confirmed 38.5 % ORR with stable duration. T-cell data shows the vaccine is working, but no "extreme" outcomes. • Narrative: De-risking of the platform, but the market will wait for Abili-T (2027) before full repricing. • Price Target: NOK 4.50 – 6.00 (Normalization to the levels before February's panic fall). 🚀 BULL Case: "The EyeBio-Moment" • Data: "Spider Plots" showing Durable Response (9+ months), TCR evidence for vaccine cells inside the tumor, and perhaps a conversion from PR to CR (tumor completely gone). • Narrative: Nykode doubles the effect of standard treatment. The comparison with Merck's acquisition of EyeBio ($1.3 billion upfront for early-stage data) becomes impossible to ignore. • Price Target: NOK 12.00 – 18.00 (The market begins to price in a real acquisition probability). 🔍 What should we look for on the slides? 1. Spider Plots: Look for flat lines below the -30 % threshold. Duration is everything! 2. TCR-graphs: Evidence that the vaccine T-cells actually find their way into the tumor. 3. Ongoing Responses: Small arrows at the end of the graphs, meaning the patient is still alive and responding. Summary: On March 20 at 15:15 in Sevilla, we will get the answer whether the technology is worth 13 øre or 60 kroner. With a downside that is practically covered by cash, the risk/reward ratio is unique. Thoughts? Anything else we should look for or that hasn't been considered?
- ·1 päivä sittenAnyone starting to realize that the stock is dirt cheap? About time.
- ·1 päivä sitten · MuokattuCan there be a bid for the company!? Of course, but what is the probability? 📍Time aspect; well, by the end of the year 📍Price; 10ish probably makes the major shareholders move 📍More players entering the field? Well 📍The company is tired of Norway and the stock exchange here, I think they would gladly see a listing and fresh start elsewhere. 📍Am I speculating? YES 📍Am I long? YES1 päivä sitten1 päivä sittenI don't think it's unthinkable that the therapy has a value of 2B dollars. Divide that by 326 million outstanding shares that's around 6 dollars per share? Or am I being too optimistic? Then there's other therapies in the pipeline on top....·1 päivä sittenVery good timing on that calculation, Mr. Parker. As we see in today's price development towards 3.3 kr, the bottom at 2.892kr has proven to be the 'floor' that fundamental values require. To elaborate on your valuation discussion with the latest figures from the Q4 report: 1. Liquidation Value (Cash Floor): With a cash balance of approx. 582 mill. kr (60.3 mill. USD) and the impending tax refund of 325 mill. kr, Nykode has a 'liquidation value' of approx. 2.78 kr per share. • At price 2.91 kr: The market valued the technology at only 13 øre per share. • At price 3.30 kr: The market now values the technology at 52 øre per share. 2. Decision in the tax case in 1H 2026: The company confirmed last week that they expect a decision during the first half of the year. This removes much of the dilution threat (emission fear) that has kept the price down. If an analysis of an asset value of 2 mrd. dollar materializes, today's pricing of the technology (52 øre) is still an extreme undervaluation compared to the 60 kr per share such a value would imply. 3. Strategic Option (Merck/MSD): When we look at Merck's acquisition of EyeBio (AMD) for 1.3 mrd. USD upfront with data from only approx. 30 patients, the parallel to Nykode's current position is striking. We are only weeks away from complete data documentation on ICHNO March 20. That the price is now reacting up from the 2.89-level indicates that investors are starting to see the same as us: That the risk/reward ratio is completely unique when one can buy a platform with a confirmed 38.5 % response rate at a price that barely exceeds the value of the cash in the till.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 300 | - | - | ||
| 2 166 | - | - | ||
| 2 575 | - | - | ||
| 1 574 | - | - | ||
| 87 | - | - |
Ylin
3,59VWAP
Alin
3,18VaihtoMäärä
5,3 1 559 379
VWAP
Ylin
3,59Alin
3,18VaihtoMäärä
5,3 1 559 379
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
2025 Q4 -tulosraportti
8 päivää sitten
‧36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
1,00 NOK/osake
Viimeisin osinko
30,54%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenIf phase-2 or early phase-3 data are strong, a large pharmaceutical company often buys the technology. Any thoughts on that here? It's annoying to invest in a journey one can believe in, only for it to abruptly stop with a typical acquisition. Regards from someone who eventually hopes to be part of the whole journey.·1 t sittenPersonally, I operate with a three-digit number at acquisition. Then what happens, happens. Today's trading indicates that some do not believe the same as me.
- ·4 t sitten🧪 Breakthrough in Boston: ASIT Summit (March 3, 2026) Nykode has now delivered what is called "Preclinical Proof of Concept" (PoC) for its tolerance platform. While the cancer vaccine teaches the body to attack, this technology teaches the immune system to calm down (tolerate). • Breakthrough in Vitiligo: New data shows a significant reduction in CD8+ T-cells in the skin. In Vitiligo, it is precisely these cells that mistakenly attack the pigment cells. This proves for the first time that the platform works on autoimmune skin conditions. [Source: Nykode Press Release, 03.03.2026] • Regulatory T-cells (Tregs): The presentation documented that Nykode's targeting of APC receptors creates Tregs. These are the body's "peacekeepers" that switch off inflammation without otherwise weakening the immune system. This is the "holy grail" in autoimmunity. [Source: Nykode Press Release, 03.03.2026] • Effect after disease onset: In models for Multiple Sclerosis (EAE), the treatment reduced auto-antibodies even when administered after symptoms had appeared – a critical proof for clinical use in humans. [Source: Nykode Q4 report p. 21, 25.02.2026] 💰 Market Potential and Valuation Many underestimate the value of early-stage data, but in the field of immune tolerance, large pharmaceutical companies (Big Pharma) often pay billions to secure the technology before it reaches human studies. • Vitiligo Market: Globally, the market for Vitiligo treatment is estimated at approximately 1.7 billion dollars in 2026, with an expected growth to over 2.2 billion dollars by 2031. Biological therapies are growing fastest at over 15% annually. [Source: Mordor Intelligence / Business Research Company, Feb 2026] • Comparable deals: * Sonoma Biotherapeutics: Received 75 million dollars upfront (approx. 800 million NOK) from Regeneron for a similar Treg platform. [Source: Regeneron/Sonoma PR, 11.01.2023] • Anokion: Eli Lilly has invested over 100 million dollars in a platform with the same mechanism as Nykode's ASIT. [Source: Eli Lilly Partnership Update, 2024] 📈 Updated Scenarios (Bear, Base, Bull) At today's share price of 3.53 kr, the technology is valued at only approx. 70 øre above the company's pure liquidation value (cash + tax claim). 1. BEAR CASE: "Oncology disappointment" If the detailed data in Seville (March 20) shows that the cancer response is not durable. • Price target: 2.50 – 2.80 kr. • Assessment: The floor in the stock has now been significantly raised because the ASIT platform functions as a validated «Asset B». The downside is practically covered by cash (1.84 kr) and the tax claim (1.00 kr). [Source: Cash calculation based on Q4 report p. 5, 25.02.2026] 2. BASE CASE: "Normalization" If the cancer data on March 20 confirms 38.5% response with stable duration. • Price target: 6.50 – 8.50 kr. • Assessment: The market is starting to price Nykode as a platform company with two legs. The risk is no longer binary, and the valuation will approach historical multiples for phase 2 companies. 3. BULL CASE: "The Big Exit" If the Seville data shows deep, durable responses (TCR proof) while ASIT interest increases. • Price target: 16.00 – 22.00 kr. • Assessment: This scenario prices in a value equivalent to Merck's acquisition of EyeBio ($1.3 billion upfront). With such a valuation, both a global cancer vaccine and a leading tolerance platform are reflected. [Source: Merck/EyeBio Comparison, May 2024] ℹ️ Important information for investors For supplementary information and the actual scientific slides from the Boston presentation, follow "Scientific Publications" on Nykode's investor pages in the coming days. Disclaimer: I own shares in Nykode Therapeutics myself. This analysis is based on publicly available information and represents my own assessments. Investments in biotechnology involve very high risk, and there is no guarantee of positive returns or profit. You should always conduct your own thorough analysis before investing. 📚 Sources and URL References • Nykode Q4 2025 Financial Report (25.02.2026): Figures for cash balance (60.3 million USD) and guidance for the tax case (1H 2026). • URL: https://nykode.com/investors/financial-reports/ • Nykode Press Release - ASIT Summit Boston (03.03.2026): Details on Vitiligo data, Tregs and CD8+ reduction. • URL: https://nykode.com/media/news-and-announcements/ • Vitiligo Treatment Market Forecast (February 2026): Market size of 1.69 billion USD. • URL: https://www.mordorintelligence.com/industry-reports/vitiligo-treatment-market • Regeneron & Sonoma Biotherapeutics Partnership (11.01.2023): Upfront value of 75 million USD for Treg platform. • URL: https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sonoma-biotherapeutics-announce-collaboration/ • Eli Lilly & Anokion Partnership Update (2024/2025): Investment levels in antigen-specific tolerance. • URL: https://investor.lilly.com/news-releases/ Do you have more to add? It's good to present all data for a thorough analysis. 🧐
- ·23 t sitten🎯 Nykode: The run-up to Sevilla (March 20) – Bear, Base & Bull After weeks of "free fall," we now see signs of bottom formation around NOK 2.90–3.20. While the market has been characterized by fear, the clinical facts remain firm. Here's what we're looking for in Sevilla and what it means for the share price: 🛡️ The Foundation (Cash Floor): NOK 2.78 Before we look up, we must look down. Nykode currently has cash reserves of approx. NOK 1.78/share + a probable tax claim of NOK 1.00/share (answer expected 1H 2026). • Conclusion: At today's prices, the technology is valued at almost zero. 🐻 BEAR Case: "The Keytruda Flash" • Data: Short-lived responses (under 6 months), weak link between T-cells and tumor shrinkage. • Narrative: The market believes the results are due to luck or Keytruda alone. • Price Target: NOK 2.00 – 2.50 (Technology valued at zero, stock trades below cash value). ⚖️ BASE Case: "Solid, but Waiting" • Data: Confirmed 38.5 % ORR with stable duration. T-cell data shows the vaccine is working, but no "extreme" outcomes. • Narrative: De-risking of the platform, but the market will wait for Abili-T (2027) before full repricing. • Price Target: NOK 4.50 – 6.00 (Normalization to the levels before February's panic fall). 🚀 BULL Case: "The EyeBio-Moment" • Data: "Spider Plots" showing Durable Response (9+ months), TCR evidence for vaccine cells inside the tumor, and perhaps a conversion from PR to CR (tumor completely gone). • Narrative: Nykode doubles the effect of standard treatment. The comparison with Merck's acquisition of EyeBio ($1.3 billion upfront for early-stage data) becomes impossible to ignore. • Price Target: NOK 12.00 – 18.00 (The market begins to price in a real acquisition probability). 🔍 What should we look for on the slides? 1. Spider Plots: Look for flat lines below the -30 % threshold. Duration is everything! 2. TCR-graphs: Evidence that the vaccine T-cells actually find their way into the tumor. 3. Ongoing Responses: Small arrows at the end of the graphs, meaning the patient is still alive and responding. Summary: On March 20 at 15:15 in Sevilla, we will get the answer whether the technology is worth 13 øre or 60 kroner. With a downside that is practically covered by cash, the risk/reward ratio is unique. Thoughts? Anything else we should look for or that hasn't been considered?
- ·1 päivä sittenAnyone starting to realize that the stock is dirt cheap? About time.
- ·1 päivä sitten · MuokattuCan there be a bid for the company!? Of course, but what is the probability? 📍Time aspect; well, by the end of the year 📍Price; 10ish probably makes the major shareholders move 📍More players entering the field? Well 📍The company is tired of Norway and the stock exchange here, I think they would gladly see a listing and fresh start elsewhere. 📍Am I speculating? YES 📍Am I long? YES1 päivä sitten1 päivä sittenI don't think it's unthinkable that the therapy has a value of 2B dollars. Divide that by 326 million outstanding shares that's around 6 dollars per share? Or am I being too optimistic? Then there's other therapies in the pipeline on top....·1 päivä sittenVery good timing on that calculation, Mr. Parker. As we see in today's price development towards 3.3 kr, the bottom at 2.892kr has proven to be the 'floor' that fundamental values require. To elaborate on your valuation discussion with the latest figures from the Q4 report: 1. Liquidation Value (Cash Floor): With a cash balance of approx. 582 mill. kr (60.3 mill. USD) and the impending tax refund of 325 mill. kr, Nykode has a 'liquidation value' of approx. 2.78 kr per share. • At price 2.91 kr: The market valued the technology at only 13 øre per share. • At price 3.30 kr: The market now values the technology at 52 øre per share. 2. Decision in the tax case in 1H 2026: The company confirmed last week that they expect a decision during the first half of the year. This removes much of the dilution threat (emission fear) that has kept the price down. If an analysis of an asset value of 2 mrd. dollar materializes, today's pricing of the technology (52 øre) is still an extreme undervaluation compared to the 60 kr per share such a value would imply. 3. Strategic Option (Merck/MSD): When we look at Merck's acquisition of EyeBio (AMD) for 1.3 mrd. USD upfront with data from only approx. 30 patients, the parallel to Nykode's current position is striking. We are only weeks away from complete data documentation on ICHNO March 20. That the price is now reacting up from the 2.89-level indicates that investors are starting to see the same as us: That the risk/reward ratio is completely unique when one can buy a platform with a confirmed 38.5 % response rate at a price that barely exceeds the value of the cash in the till.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 300 | - | - | ||
| 2 166 | - | - | ||
| 2 575 | - | - | ||
| 1 574 | - | - | ||
| 87 | - | - |
Ylin
3,59VWAP
Alin
3,18VaihtoMäärä
5,3 1 559 379
VWAP
Ylin
3,59Alin
3,18VaihtoMäärä
5,3 1 559 379
Välittäjätilasto
Dataa ei löytynyt